IRONWOOD PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $528.45 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2022-02-18
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-12-31 was $43.20M, a 9.72% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-09-30 was $34.42M, a 66.71% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-06-30 was $25.20M, a 105.19% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-03-31 was $3.35M.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was $528.45M, a 397.71% increase from fiscal 2020.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was $106.18M, a 80.13% increase from fiscal 2019.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2019 was $58.94M.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2018 was -$194.15M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2021-12-31 | $528.45M 10-K · filed 2022-02-18 | |||
| 2020-12-31 | $43.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $77.63M derived: sum of 2 quarters · filed 2022-02-18 | $102.83M derived: sum of 3 quarters · filed 2022-02-18 | $106.18M 10-K · filed 2022-02-18 |
| 2020-09-30 | $34.42M 10-Q · filed 2020-11-05 | $59.63M derived: sum of 2 quarters · filed 2020-11-05 | $62.97M 10-Q · filed 2020-11-05 | $110.83M derived: sum of 4 quarters · filed 2021-02-17 |
| 2020-06-30 | $25.20M 10-Q · filed 2020-08-06 | $28.55M 10-Q · filed 2020-08-06 | $76.41M derived: sum of 3 quarters · filed 2021-02-17 | $97.06M derived: sum of 4 quarters · filed 2021-02-17 |
| 2020-03-31 | $3.35M 10-Q · filed 2020-05-06 | $51.20M derived: sum of 2 quarters · filed 2021-02-17 | $71.85M derived: sum of 3 quarters · filed 2021-02-17 | $84.13M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-12-31 | $47.86M 10-K · filed 2021-02-17 | $68.51M derived: sum of 2 quarters · filed 2021-02-17 | $80.79M derived: sum of 3 quarters · filed 2021-02-17 | $58.94M 10-K · filed 2022-02-18 |
| 2019-09-30 | $20.65M 10-K · filed 2021-02-17 | $32.93M derived: sum of 2 quarters · filed 2021-02-17 | $11.09M 10-Q · filed 2020-11-05 | $19.46M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-06-30 | $12.28M 10-K · filed 2021-02-17 | -$9.56M 10-Q · filed 2020-08-06 | -$1.19M derived: sum of 3 quarters · filed 2021-02-17 | -$153.01M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-03-31 | -$21.85M 10-K · filed 2021-02-17 | -$13.47M derived: sum of 2 quarters · filed 2021-02-17 | -$165.30M derived: sum of 3 quarters · filed 2021-02-17 | -$189.43M derived: sum of 4 quarters · filed 2021-02-17 |
| 2018-12-31 | $8.37M 10-K · filed 2020-02-13 | -$143.45M derived: sum of 2 quarters · filed 2020-02-13 | -$167.59M derived: sum of 3 quarters · filed 2020-02-13 | -$194.15M 10-K · filed 2021-02-17 |
| 2018-09-30 | -$151.82M 10-K · filed 2020-02-13 | -$175.96M derived: sum of 2 quarters · filed 2020-02-13 | -$202.52M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | -$24.14M 10-K · filed 2020-02-13 | -$50.70M 10-Q · filed 2019-07-30 | ||
| 2018-03-31 | -$26.56M 10-K · filed 2020-02-13 | |||
| 2017-12-31 | -$54.91M 10-K · filed 2020-02-13 | |||
| 2012-12-31 | -$43.85M 10-K · filed 2013-02-21 | $3.78M derived: sum of 2 quarters · filed 2013-02-21 | -$37.02M derived: sum of 3 quarters · filed 2013-02-21 | -$72.62M 10-K · filed 2013-02-21 |
| 2012-09-30 | $47.63M 10-K · filed 2013-02-21 | $6.83M derived: sum of 2 quarters · filed 2013-02-21 | -$28.77M derived: sum of 3 quarters · filed 2013-02-21 | -$35.74M derived: sum of 4 quarters · filed 2013-02-21 |
| 2012-06-30 | -$40.80M 10-K · filed 2013-02-21 | -$76.40M derived: sum of 2 quarters · filed 2013-02-21 | -$83.38M derived: sum of 3 quarters · filed 2013-02-21 | -$104.01M derived: sum of 4 quarters · filed 2013-02-21 |
| 2012-03-31 | -$35.60M 10-K · filed 2013-02-21 | -$42.58M derived: sum of 2 quarters · filed 2013-02-21 | -$63.21M derived: sum of 3 quarters · filed 2013-02-21 | -$82.05M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-12-31 | -$6.97M 10-K · filed 2013-02-21 | -$27.61M derived: sum of 2 quarters · filed 2013-02-21 | -$46.45M derived: sum of 3 quarters · filed 2013-02-21 | -$64.85M 10-K · filed 2013-02-21 |
| 2011-09-30 | -$20.63M 10-K · filed 2013-02-21 | -$39.48M derived: sum of 2 quarters · filed 2013-02-21 | -$57.88M 10-Q · filed 2011-11-09 | -$69.53M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | -$18.84M 10-K · filed 2013-02-21 | -$37.24M 10-Q · filed 2011-08-12 | -$48.90M derived: sum of 3 quarters · filed 2013-02-21 | -$62.01M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | -$18.40M 10-K · filed 2013-02-21 | -$30.05M derived: sum of 2 quarters · filed 2013-02-21 | -$43.17M derived: sum of 3 quarters · filed 2013-02-21 | -$60.33M derived: sum of 4 quarters · filed 2013-02-21 |
| 2010-12-31 | -$11.65M 10-K · filed 2012-02-29 | -$24.77M derived: sum of 2 quarters · filed 2012-02-29 | -$41.93M derived: sum of 3 quarters · filed 2012-02-29 | -$56.41M 10-K · filed 2013-02-21 |
| 2010-09-30 | -$13.11M 10-K · filed 2012-02-29 | -$30.28M derived: sum of 2 quarters · filed 2012-02-29 | -$44.76M 10-Q · filed 2011-11-09 | |
| 2010-06-30 | -$17.16M 10-K · filed 2012-02-29 | -$31.65M 10-Q · filed 2011-08-12 | ||
| 2010-03-31 | -$14.48M 10-K · filed 2012-02-29 | |||
| 2009-12-31 | -$60.00M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |